FDA Accepts Supplemental Application for ORSERDU (Elacestrant Hydrochloride)
The FDA has accepted a supplemental application for ORSERDU (elacestrant hydrochloride) from Stemline Therapeutics.
Asset / Drug
Drug and asset intelligence for ORSERDU with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Hormonal Therapy
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.